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Abstract
Background: The development and progression of estrogen receptor alpha positive (ERα+) breast cancer has been
linked epidemiologically to prolactin. However, activation of the canonical mediator of prolactin, STAT5, is associated with
more differentiated cancers and better prognoses. We have reported that density/stiffness of the extracellular matrix
potently modulates the repertoire of prolactin signals in human ERα+ breast cancer cells in vitro: stiff matrices shift the
balance from the Janus kinase (JAK)2/STAT5 cascade toward pro-tumor progressive extracellular regulated kinase (ERK)1/2
signals, driving invasion. However, the consequences for behavior of ERα + cancers in vivo are not known.
Methods: In order to investigate the importance of matrix density/stiffness in progression of ERα + cancers, we examined
tumor development and progression following orthotopic transplantation of two clonal green fluorescent protein (GFP)
+ ERα+ tumor cell lines derived from prolactin-induced tumors to 8-week-old wild-type FVB/N (WT) or collagen-dense
(col1a1tm1Jae/+) female mice. The latter express a mutant non-cleavable allele of collagen 1a1 “knocked-in” to the col1a1
gene locus, permitting COL1A1 accumulation. We evaluated the effect of the collagen environment on tumor
progression by examining circulating tumor cells and lung metastases, activated signaling pathways by
immunohistochemistry analysis and immunoblotting, and collagen structure by second harmonic generation microscopy.
Results: ERα + primary tumors did not differ in growth rate, histologic type, ERα, or prolactin receptor (PRLR) expression
between col1a1tm1Jae/+ and WT recipients. However, the col1a1tm1Jae/+ environment significantly increased circulating
tumor cells and the number and size of lung metastases at end stage. Tumors in col1a1tm1Jae/+ recipients displayed
reduced STAT5 activation, and higher phosphorylation of ERK1/2 and AKT. Moreover, intratumoral collagen fibers in
col1a1tm1Jae/+ recipients were aligned with tumor projections into the adjacent fat pad, perpendicular to the bulk of the
tumor, in contrast to the collagen fibers wrapped around the more uniformly expansive tumors in WT recipients.
Conclusions: A collagen-dense extracellular matrix can potently interact with hormonal signals to drive metastasis of ERα
+ breast cancers.
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Background
Metastatic estrogen receptor α positive (ERα+) breast can-
cer is the leading cause of breast cancer mortality [1–3].
However, the mechanisms that drive progression of these
cancers are poorly understood, in part because there are
few animal models of ERα + breast cancer. The extracellu-
lar matrix (ECM) is increasingly recognized as an import-
ant contributor to tumor behavior. Aggressive tumors
frequently display desmoplasia, one component of which
is increased deposition of fibrillar collagens such as
collagen-I [4–6]. This increased matrix deposition fre-
quently increases the stiffness of the tumor and adjacent
tissue [7]. Stiff ECM environments drive tumor-
progressive characteristics both in vitro [8] and in mouse
models [9–11]. Moreover, tumors can actively remodel
the surrounding ECM. Aligned collagen-I fibers increase
ECM stiffness [12], and collagen fibers aligned perpen-
dicularly to the boundary of larger tumors predict poor
outcomes, particularly of ERα + cancers [13]. Collagen-I
density/stiffness increases pro-tumorigenic signaling cas-
cades in tumor epithelia, such as focal adhesion kinase
(FAK), src family kinases (SFKs), and extracellular regu-
lated kinase (ERK)1/2 [14]. The effects of these changes
on hormonal signals and consequences for their roles in
the progression of ERα + tumors are not well-understood.
Large prospective epidemiologic studies have linked
the hormone, prolactin (PRL), to increased risk of devel-
opment of aggressive ERα + cancers, and smaller-scale
studies also suggest that it contributes to their progres-
sion [15–18]. However, activation of STAT5, the primary
physiological effector of prolactin (PRL), is associated
with favorable clinical outcomes [19–21], and reduces
invasion of breast cancer cells in vitro [22, 23]. Interest-
ingly, FAK, SFKs, and ERK1/2 are also activated by PRL
[24–26], and the ability of PRL to activate STAT5 is
inversely related to its ability to activate AP-1 via
mitogen-activated protein (MAP) kinases and augment
invasiveness [27]. We recently reported that collagen-I
density/stiffness is a major determinant of the signaling
pathways that are available to the PRL receptor (PRLR).
Whereas ERα + breast cancer cells cultured in low dens-
ity/compliant three-dimensional collagen I matrices
respond to PRL predominantly by activating physio-
logical JAK2/STAT5 signals, high density/stiff matrices
shift PRL responses to pathological ERK1/2 signals and
increase invasiveness [28]. Under these latter conditions,
PRL crosstalk with estrogen increases alignment of the
matrix perpendicular to the tumor edge [29], similar to
that correlated with decreased survival of patients with
ERα + tumors [13, 30]. These data indicate that PRL and
the ECM cooperate to drive processes leading to
progression of breast cancer. However, examination of
this interplay in vivo is necessary to confirm its import-
ance and investigate clinical applications.
In order to examine the interaction between PRL and
increased collagen-I deposition in an immunocompetent
environment in vivo, we took advantage of well-
characterized genetically modified mouse models. Hor-
monally responsive mouse models of breast cancer are
rare [31, 32]. The neu-related lipocalin-prolactin (NRL-
PRL) transgenic mouse mimics the local PRL synthesis
in the mammary glands of women. Nulliparous female
mice spontaneously develop aggressive mammary
tumors, about 75% of which are ERα + [33]. ERα + tumor
cell lines derived from these adenocarcinomas are read-
ily transplantable to syngeneic recipients [34]. To model
increased collagen I, we utilized the Col1a1tmJae1mouse
[35]. Mutation of the MT1-MMP cleavage site in Col1a1
reduces collagen-I turnover, leading to its accumulation,
without a need for additional fibrotic factors and any as-
sociated confounding activities. We have previously
shown that this increases metastasis from experimental
MMTV-PyMT-induced mammary tumors, and results in
a collagen fiber signature that predicts poor survival in
patients with breast cancer [13, 14, 36].
Here, we orthotopically transplanted clonal green
fluorescent protein (GFP)-labeled PRL-induced ERα +
mammary tumor cell lines into syngeneic wild-type
(WT) or heterozygous mutant collagen-I female mice
(Col1a1tmJae/+, mCol1a1). Tumors that developed in the
mCol1a1 environment had similar rates of growth,
morphology, ERα, and PRLR expression to those in the
WT collagen environment. However, the mCol1a1 envir-
onment increased circulating tumor cells (CTCs), and
the number and size of lung metastases. It also altered
the pattern of activated signaling cascades in the primary
tumors: tumors in mCol1a1 female mice had lower
pSTAT5 and increased pERK1/2 and pAKT expression,
consistent with predictions from in vitro studies. More-
over, the alignment of intratumoral collagen fibers near
the tumor boundary in mCol1a1 recipients was more
perpendicular to the tumor edge and oriented in parallel
to protrusions invading into the adjacent fat pad. These
data indicate that extracellular matrix can potently inter-
act with hormonal signals to drive the development of
metastasis from ERα + breast cancers.
Methods
Reagents
Antibodies used in these studies were purchased from
the following vendors: ERK1/2 (#9102), pERK1/2
(#9101), AKT (#9272), pAKT S473 (#9271), pAKT S473
(#3787S, for immunohistochemical analysis) from Cell
Signaling Technology (Danvers, MA, USA); pSTAT5
(#71-6900) from Invitrogen (Grand Island, NY, USA);
ERα (#sc-542), PRLR (#sc-20992), STAT5 (#sc-835x)
from Santa Cruz Biotechnology (Santa Cruz, CA, USA);
eGFP (#AB6658) from AbCam (Cambridge, MA, USA);
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PR (#A0098) from Dako (Carpinteria, CA, USA);
biotinylated goat anti-rabbit (#BA-100) from Vector
Labs (Burlingame, CA, USA); pan-actin (#125-ACT)
from Phosphosolutions (Aurora, CO, USA); APC-
conjugated CD31 (#551262) and CD45 (#559864) from
BD Biosystems (San Jose, CA, USA). Avidin-biotin
complex (ABC) (#PK-4000) and ImmPACT DAB (#SK-
4105) were purchased from Vector Labs (Burlingame,
CA, USA). All other reagents were obtained from Fisher
Scientific or Sigma-Aldrich.
Cell lines and culture
ERα +mouse mammary tumor cell lines were derived
from a NRL-PRL mammary tumor [34, 37]. Two inde-
pendently derived cell lines were stably transfected with
eGFP, TC2GR12 (TC2) and TC4GR5 (TC4), and clonal
sublines were maintained on tissue culture plastic in
Roswell Park Memorial Institute medium (RPMI) 1640
supplemented with 10% FBS, 1% penicillin/streptomycin,
and 1 mg/ml (TC2GR12) or 400 μg/ml (TC4GR5) puro-
mycin as a selection factor. As shown in Additional file
1, TC2GR12 (TC2) and TC4GR5 (TC4) both express the
rPRL transgene and exhibit somewhat differing levels of
hormone receptor and signal effector proteins.
Animals
Mice heterozygous for Col1a1tmJae [35] (Col1a1tmJae/+;
mCol1a1) were backcrossed onto the FVB/N strain back-
ground for 10 generations. Mice were housed and cared
for in accordance with the Guide for Care and Use of La-
boratory Animals in AAALAC-accredited facilities. All
procedures were approved by the University of
Wisconsin-Madison Animal Care and Use Committee.
For some experiments, 2.5 × 104 (TC2GR12) or 7.5 × 104
(TC4GR5) cells in 50 μl of sterile PBS were orthotopically
injected into the left caudal mammary fat pads of 8 to 10-
week-old FVB/N WT or mCol1a1 female mice and
allowed to progress to end stage (tumor 1.5 cm in diam-
eter). All recipients survived to end stage. For analysis of
early-stage tumors, cell lines were injected bilaterally into
the caudal mammary fat pads of 8 to 10-week-old WT or
heterozygous mCol1a1 female mice, and tumors were
allowed to progress for 17 days (TC2) or 24 days (TC4),
the time of peak CTCs, respectively, before collection.
Each animal was palpated biweekly to assess tumor devel-
opment, and tumor diameter was measured using elec-
tronic calipers. Tumor volume was calculated as the
largest diameter * (smallest diameter2) * 0.4.
Flow cytometry
Peripheral blood (100 μl) was collected from each animal
weekly from a maxillary vein in 6 U heparin sulphate,
starting 3 days after tumor cell transplantation. Red
blood cells were lysed in 0.15 M NH4Cl + 1.2 mM EDTA
for 10 minutes with gentle agitation. Cleared blood was
centrifuged at 300 × g for 5 minutes, washed in PBS, and
stained with anti-CD31/APC (1:100) and anti-CD45/
APC (1:100) for 30 minutes on ice to label
hematopoietic cells. The labeled cell suspension was
then washed, fixed in 2% paraformaldehyde, and ana-
lyzed for endogenous GFP and CD31/45+ hematopoietic
cells on a BD Fortessa flow cytometer, using the gating
strategy presented in Additional file 2. Seven blood sam-
ples from non-injected female mice (five WT, two
mCol1a1) served as controls for each experiment, and
average background auto-fluorescence was subtracted
from the experimental results.
Immunohistochemical analysis and immunofluorescence
Immunohistochemical analyses were performed as
previously described [38]. Briefly, tissues were fixed in
10% neutral buffered formalin, embedded in paraffin,
and serial-sectioned. Deparaffinized tissues were hy-
drated in decreasing concentrations of ethyl alcohol
(EtOH) and endogenous peroxidase activity quenched
in 3% H2O2 in methanol (MeOH). Dilutions of the
primary antibodies, antigen retrieval, and blocking
conditions are shown in Additional file 3. Secondary
antibody (1:250) and signal amplification (avidin-bio-
tin complex (ABC)) were performed at room
temperature prior to chromogen-detection with
ImmPACT 3,3-diaminobenzidine (DAB) according to
the manufacturer’s instructions. Tissues were counter-
stained with hematoxylin, dehydrated, and mounted
for microscopic analysis. For immunofluorescence
experiments, tissues were processed as described
without performing peroxidase quenching. Alexa-488
conjugated streptavidin (1:100) was incubated at room
temperature for 1 h prior to mounting with anti-fade
media and subsequent epifluorescence imaging.
Lung metastasis analysis
All animals were allowed to progress to end stage
(tumor diameter 1.5 cm). At this time, lungs were col-
lected and fixed in 10% neutral buffered formalin. After
24 h, surface nodules on all lung lobes were counted
under a dissection microscope. The left lobe was then
sectioned in four step-sections of 50 μm with two serial
sections at each step. GFP immunofluorescence was per-
formed as described to assess micrometastatic load.
Total numbers of GFP+ lesions were counted per × 10
field of view (FOV) over seven FOVs per lung. The area
of each lesion was calculated and the total sum of lesion
area determined per FOV. Three independent lungs
were analyzed for each cell line/genotype combination
over two 50-μm steps, using ImageJ [39].
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Immunoblotting
Snap-frozen tumor pieces were homogenized in ice cold
40 mM Tris, 276 mM NaCl, 20% glycerol, 2% NP-40,
4 mM EDTA, 20 mM NaF, 2 mM sodium orthovana-
date, 40 μg/ml phenylmethane sulfonylfluoride (PMSF),
and 50 μg/ml aprotinin. Briefly, 30 μg of tumor hom-
ogenate was fractionated by SDS-PAGE, transferred to
polyvinylidene fluoride (PVDF) membranes, and then
probed with appropriate antibodies (ERK1/2, 1:2000;
pERK1/2, 1:5000; STAT5, 1:50000; pSTAT5, 1:1000; E
Rα, 1:1000; AKT, 1:2000; pAKT S473, 1:1000; PRLR,
1:1000). Signals were visualized by enhanced chemilu-
minescence and quantified by densitometry (UVP
Visionworks). All end-stage tumors were analyzed.
Collagen imaging and analysis
Paraffin-embedded, 5-μm sections of early lesions were
stained with picrosirius red as previously described [40].
Polarized light microscopy with a × 10 objective was uti-
lized to assess birefringence that is specific to fibrillar
collagens. Multiphoton microscopy and second
harmonic generation (SHG) imaging were performed as
previously described [41]. Briefly, collagen was visualized
with a laser excitation of 890 nm with a 445 ± 20 nm
emission filter to detect backwards SHG focused on the
sample with a × 20/0.75NA objective. The overall fiber
alignment analysis was performed with the CurveAlign
software following fiber detection utilizing CT-FIRE
[42, 43]. The alignment coefficient was based on the
orientation of the collagen fibers in the same image
and ranges from 0 to 1, where the larger the
alignment coefficient, the more aligned the fibers.
Statistical analysis
Statistical analyses were performed in GraphPad Prism
v4.0 or SAS/STAT v9.4. Data were tested for normality
using the Shaprio-Wilk test. Data were analyzed using
the unpaired t tests (normal data) or Mann-Whitney U
non-parametric test (non-normal data) as indicated.
Tumor growth and CTC data were analyzed using two--
way repeated measures analysis of variance (ANOVA),
taking into account values across days in the same ani-
mals. Collagen alignment was quantified using repeated
measure group comparison with the SAS Proc Mixed
model to take into account image–image and tumor −
tumor variation for each cell line/genotype combination.
Significance of the data are presented as *p < 0.05, **p <
0.01, ***p < 0.001, or ****p < 0.0001.
Results
Increasing collagen-I does not alter primary tumor
growth, yet increases circulating tumor cells
In order to study the effect of a collagen-dense environ-
ment on progression of PRL-induced ERα +mammary
cancer, we orthotopically transplanted GFP+ TC2 or
TC4 tumor cells into WT or mCol1a1 female mice and
monitored growth until end stage. Increased collagen-I
did not alter the growth of either TC2 or TC4 tumors
(Fig. 1a-b). In order to assess the mobilization of tumor
epithelia into the bloodstream as an indicator of meta-
static potential, peripheral blood was collected weekly
from the maxillary vein and analyzed for circulating GFP
+ tumor cells (CTCs) as described in “Methods”. In
mCol1a1 recipients of both TC2 and TC4 cells, CTCs
were significantly higher than in WT recipients (Fig. 1b,
TC2, p < 0.0050; TC4, p < 0.0320). Interestingly, levels of
CTCs peaked considerably prior to end stage (TC2, day
17; TC4, day 31 after transplantation).
Collagen-I does not change tumor histology or hormone
receptor status
Transplantation of both TC2 and TC4 cell lines resulted
in spindle cell carcinomas in both WT and mCol1a1
recipients (Fig. 2a). As expected, tumors in mCol1a1 ani-
mals showed increased Masson’s trichrome staining near
the tumor boundary compared to those in WT mice,
reflecting increased connective tissue in this mutated
environment (Fig. 2b). Like the parent cell lines, TC
tumors were also ERα+, and collagen deposition did not
alter ERα expression discerned by either immunohisto-
chemical (Fig. 2c) or western analyses (Fig. 2d). PRLR
expression in these tumors was not altered by collagen
accumulation (Additional file 4A); progesterone receptor
(PR) was expressed in localized foci (Additional file 4B).
Metastasis of ERα +mammary tumors is enhanced by
increasing collagen-I
ERα + breast cancers metastasize to multiple peripheral
tissues, including the lungs [44]. As the mCol1a1 back-
ground increased CTCs (Fig. 1b), we collected the lungs
at end stage to determine the consequences for metasta-
sis to this site. Significantly more surface lung nodules
were found in mCol1a1 recipients of both TC2 and TC4
cells (Fig. 3a, b; Additional file 5). Histologic examin-
ation revealed that mCol1a1 female mice bearing either
TC2 or TC4 tumors also had higher numbers of
metastatic lesions in the lung parenchyma (Fig. 3c,
d) (p < 0.0001), visualized utilizing GFP as a marker
(Fig. 3j, k, n, o). Moreover, these lesions were
significantly larger (Fig. 3e, f ) (p < 0.01), resulting in
a greatly increased total metastatic burden in
mCol1a1 mice (Fig. 3g, h) (p < 0.0001).
mCol1a1 decreases pSTAT5, and increases pERK1/2 and
pAKT in ERα +mammary tumors
We have previously shown that characteristics of the
collagen ECM alter the spectrum of PRL-induced signals
with behavioral consequences in human breast cancer
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cells in vitro: stiff/dense matrices reduce signals to
STAT5, while increasing signals through ERK1/2 [28,
29]. While high pSTAT5 is associated with increased dif-
ferentiation and lower proliferation [19–21], signals
through ERK1/2 increase proliferation of breast cancer
cells and may contribute to tumor progression [14, 45].
Activation of AKT is associated with metastatic ERα +
breast cancer, and the efficacy of anti-estrogens in com-
bination with therapies targeting this pathway are
currently under clinical evaluation [46, 47]. To deter-
mine if the high collagen-I environment in vivo alters
these signaling cascades, we performed immunoblotting
and immunohistochemical analyses. Tumors that grew
from both cell lines in mCol1a1 recipients had lower
pSTAT5 (p < 0.05, Fig. 4a, d), similar to human breast
cancer cells cultured in dense/stiff matrices in vitro. TC2
tumors had higher pERK1/2 in mCol1a1 female mice,
compared to WT recipients (p < 0.05, Fig. 4b), while
TC4 tumors trended similarly (p = 0.11, Fig. 4e). Simi-
larly, relative levels of pAKT were significantly higher in
tumors from both cell lines (p < 0.05, Fig. 4c, f ). These
results were confirmed by immunohistochemical
analysis, with lower nuclear pSTAT5 staining in tumors
in mCol1a1 compared to WT recipients (Fig. 4g)
(Additional file 6A), and higher nuclear and cytoplasmic
pERK1/2 and pAKT in mCol1a1 female mice bearing
TC2 (Fig. 4h, i) and TC4 (Additional file 6B, C) tumors.
Early tumors in mCol1a1 recipients exhibit finger-like
protrusions containing aligned collagen fibers
At end stage, tumors nearly fill the mammary fat pads.
In order to examine the characteristics of the tumor
boundaries, we examined lesions earlier after transplant-
ation, at the time when CTCs were elevated, particularly
in mCol1a1 recipients (day 17, TC2 or day 24, TC4;
Fig. 1b). Early-stage tumors in both WT and mCol1a1
recipients exhibited the spindle cell morphology evident
at end stage (Fig. 5a). However, the tumor boundaries
were quite different in the two host genotypes. Whereas
both TC2 and TC4 tumors in WT recipients displayed a
generally uniform pattern of expansion, lesions in
mCol1a1 hosts exhibited many vascular finger-like pro-
trusions into the surrounding mammary fat pads (Fig. 5b,
c). Picrosirius red staining with polarized light
Fig. 1 mCol1a1 does not alter the rate of tumor growth, but increases circulating tumor cells. a-b Tumor growth of tumor cell line (TC)2 (a) and
TC4 (b) tumors until collection of the largest tumors began. Tumor volume was measured biweekly. Mean ± SEM TC2 animals: wild-type (WT)
n = 7, mCol1a1 n = 6. TC4 animals: WT n = 7, mCol1a1 n = 8. Time significantly influenced tumor volume in both TC2 (a) and TC4 (b) tumors
(p < 0.0001, two-way repeated measures ANOVA), but genotype did not. c-d Circulating tumor cells (CTCs) in peripheral blood of animals bearing
TC2 (c) or TC4 (d) tumors. Peripheral blood was collected weekly and analyzed for green fluorescent protein positive (GFP+) CTCs as described in
“Methods”. Mean ± SEM TC2 recipients: WT n = 7, mCol1a1 n =6. TC4 recipients: WT n = 7, mCol1a1 n =8. Genotype significantly altered levels of
CTCs (TC2, p < 0.0050; TC4, p < 0.0320; repeated measure two-way ANOVA, taking into account values across days in the same animals). Levels of
CTCs peaked when tumors were relatively small, regardless of genotype (TC2, day 17 is significantly different from all other days except day 38,
*p < 0.05; TC4, day 31 is significantly higher than day 17 and day 38, *p < 0.05)
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microscopy revealed dense collagen fibers that were
aligned with the tumor projections in mCol1a1 recipi-
ents, while fibers in tumors in WT animals were
wrapped around the tumor edge (Fig. 5d), similar to col-
lagen fibers observed in non-aggressive tumors [13, 48].
SHG microscopy in combination with analysis of the
alignment of collagen fibers showed that collagen fibers
in tumors of WT recipients aligned with one another
parallel to the tumor edge, while those in tumors of
mCol1a1 recipients were less consistently oriented
(Fig. 5e, f ) (p < 0.0001, TC2; p < 0.05, TC4), with many
perpendicular to the bulk of the tumor and/or aligned
with the protrusions into the fat pad.
Discussion
Metastasis of ERα + breast cancer is poorly understood.
ECM characteristics such as alignment of the collagen fi-
bers in and around the tumor correlate with poor sur-
vival [13], demonstrating the importance of this
component of the tumor microenvironment. However,
the role of hormones in these events, and the conse-
quences of changes in the ECM for hormone actions
have not been clear. While some evidence supports a
role for elevated PRL exposure in tumor progression
[18], conflicting data on PRL-induced signal effectors
suggest that other factors modulate PRL responses. We
previously demonstrated in vitro that a dense/stiff
Fig. 2 mCol1a1 does not alter tumor histologic type or hormone receptor status. Tumor cell line (TC)2 tumors (left panel) and TC4 tumors (right panel)
were collected at end stage and processed for histological analysis as described in “Methods”. a Hematoxylin and eosin stain (H&E). b Masson’s
Trichrome stain. c Estrogen receptor (ER)α immunohistochemical analysis. Original magnifications × 200; scale bar= 50 μm. d Immunoblotting of tumor
lysates with the indicated antibodies. ERα levels were normalized to total extracellular regulated kinase (ERK)1/2. Note that increased intratumoral
collagen-I in the mCol1a1 environment contributed to the protein harvested, reducing levels of signaling proteins when equal amounts of protein
were loaded. Mean ± SEM TC2 tumors: wild-type (WT) n = 7, mCol1a1 n = 6; TC4 tumors: WT n = 7, mCol1a1 n = 8. Unpaired t test, p > 0.05
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collagen-I matrix shifts the balance of PRL signals from
physiological to tumor progressive, and permits PRL and
estrogen to reorient collagen-I fibers that mimic aggres-
sive ERα + breast cancers in women [28, 29]. Here, we
report that the predictions from these studies are con-
firmed in an immunocompetent mouse model in vivo:
collagen-I accumulation promoted ERK1/2 and AKT ac-
tivation and decreased STAT5 phosphorylation in PRL-
Fig. 3 Metastasis of estrogen receptor (ER)α + tumors is enhanced by mCol1a1. a, b Nodules were counted on the surfaces of all lung lobes
under dissection microscopy. Mean ± SEM tumor cell line (TC)2 tumors (a): wild-type (WT) n = 7, mCol1a1 n = 6. TC4 tumors (b): WT n = 7,
mCol1a1 n = 8. Mann-Whitney U test, *p < 0.05, **p < 0.01. c-h Lungs were fixed and step-sectioned for histochemical analysis as detailed in
“Methods”. Green fluorescent protein positive (GFP+) lesions were counted per × 10 field of view (FOV) (c, d). The area of GFP+ lesions was
determined in ImageJ, and average size of individual lesions (e, f) and total lesion area per FOV (g, h) were calculated as described in “Methods”.
Mean ± SEM Mann-Whitney U test. **p < 0.01, ****p < 0.0001. i-o Paired hematoxylin/eosin (H&E) and GFP stained sections from animals bearing
TC4 tumors. Primary tumor (i, m), WT lung (j, n), mCol1a1 lung (k, o), and a non-GFP tumor control (l, p). Arrowheads indicate GFP+ lesions in
lungs, one enlarged in each inset. Original magnifications × 100. Scale bar = 100 μm
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Fig. 4 mCol1a1 decreases pSTAT5, and increases pERK1/2, pAKT. a-f TC2 (a-c) and tumor cell line (TC)4 (d-f) tumor lysates were analyzed by western
blotting with the indicated antibodies. Mean ± SEM TC2 tumors: wild-type (WT) n = 7, mCol1a1 n = 6; TC4 tumors: WT n = 7, mCol1a1 n = 8. Unpaired t test,
*p< 0.05. g-i Immunohistochemical analysis of pSTAT5 (g), pERK1/2 (h) and pAKT (i) in TC2 tumors. Original magnification × 200. Scale bar= 50 μm
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Fig. 5 (See legend on next page.)
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induced ERα +mammary carcinomas, driving local inva-
sion of the primary tumor, realigning collagen fibers, mo-
bilizing tumor epithelia, and enhancing pulmonary
metastases. These data indicate that the ECM can alter
hormonal signals to drive aggressive behavior of ERα + tu-
mors, providing mechanistic insight into their metastasis.
Extensive in vitro studies of human breast cancer cells
have shown that the PRLR, like other cytokine receptors,
can activate multiple signaling pathways [17]. However,
the determinants of the spectrum of signaling pathways,
and their respective roles in disease in vivo have been
unclear. In normal mammary development, PRL signals
primarily through JAK2/STAT5 to direct expansion and
differentiation of the mammary epithelia in concert with
ovarian steroids [49, 50]. Consistent with clinical data
demonstrating that high STAT5 activation in breast can-
cers predicts favorable outcomes [19–21], constitutive
activation of STAT5 in mouse models leads to well-
differentiated tumors [51]. Interestingly, signals through
this pathway are required for initiation, but not progres-
sion, of PRL-induced cancers in NRL-PRL females [52].
However, many ERα + cancers that develop in this model
are very aggressive, and display highly activated ERK1/2
and AKT [33, 38], indicating activation of non-JAK2/
STAT5 pathways. The data presented herein substantiate
that the ECM is a potent determinant of the signaling
cascades and outcomes of PRL actions in vivo, illuminat-
ing the apparent disparity between PRL exposure and
activated STAT5 in the progression of clinical breast
cancer. Moreover, our findings suggest that targeting
non-canonical PRL signals may be of therapeutic benefit.
Mammographic density is a strong predictor of breast
cancer risk [53–55]. However, epidemiologic data linking
ECM density and breast cancer aggression are inconsist-
ent [56, 57]. Mammographically dense tissue partly com-
prises increased fibrillar collagen [58]. Although this can
stiffen the ECM [7, 59], the properties of density and
stiffness are not always linked. For example, at involu-
tion following weaning, the mammary ECM contains
higher levels of collagen I, yet the ECM is less stiff than
that in the nulliparous gland [60]. This suggests a funda-
mental difference in ECM architecture between physio-
logic states and cancer which deserves further study.
Interestingly, we have observed that the ECM features -
stiffness and collagen-I ligand density - exert distinct ef-
fects on PRL-initiated signals, using polyacrylamide
hydrogels in vitro: elevated density reduces PRL phos-
phorylation of STAT5, whereas stiffness augments PRL
signals to ERK1/2 [61]. The alterations in both signaling
cascades elicited by reduced collagen I degradation and
the increase in collagen fibers aligned with invasive pro-
jections of the tumor mass observed in the current in
vivo study suggest that PRL-expressing ERα + cancer can
directly or indirectly remodel dense collagen matrices to
increase stiffness and alignment. Further, PRL itself may
contribute to collagen density. PRL and mammographic
density are epidemiologically linked [62, 63] and PRL en-
hances the expression of mammary ECM components
such as Col1a1 [64], and Tnc [65], which promotes can-
cer cell invasion [66]. Taken together with the current
data, these observations begin to outline a model where
the characteristics of PRL and ECM work together to
promote the invasion and metastasis of hormone-
responsive breast cancer.
Mouse models of ERα + breast cancer are limited, and
few develop distant metastases [31, 32]. Although patient-
derived xenografts are proving useful in elucidating the
behavior of some breast cancer subtypes in vivo, they
require highly immunocompromised hosts [67, 68], a sub-
stantial limitation in light of the accumulating evidence on
the importance of the immune response in tumor pro-
gression and metastasis [69]. Moreover, ERα + breast
tumors have been difficult to grow in mice, preventing the
widespread use of patient-derived xenografts for this sub-
type. Interestingly, mice genetically engineered to express
human PRL appear to increase successful transplantations
of human primary ERα + breast cancer [70]. Our syngen-
eic model allows examination of the behavior of ERα +
mammary cancers, including metastasis, permitting us to
demonstrate potent interactions between the features of
the ECM and PRL that drive aggression in vivo.
Conclusions
Our studies demonstrate that a collagen-I-dense ECM
can potently alter hormonal signals to drive the progres-
sion of ERα + breast cancer, increasing intravasation and
pulmonary metastases. Our data provide evidence that
increased collagen-I can shift the pattern of activated
(See figure on previous page.)
Fig. 5 Early lesions in mCol1a1 recipients display invasive protrusions that contain aligned collagen fibers. a Hematoxylin/eosin stain (H&E) of
tumor cell line (TC)2 tumors (left panels) at 17 days, TC4 tumors (right panels) at 24 days after transplantation. b Tumor edges (H&E). Arrowheads
indicate finger-like protrusions into the mammary fat pad. c Higher magnification of boxed area from (b). d Picrosirius red staining. Note
yellow-orange fibers in the protrusions in mCol1a1 tumors. Original magnification × 100. a, b, d, scale bars = 100 μm. e Second harmonic
generation (SHG) imaging of collagen fibers. Yellow dashed lines indicate tumor boundaries. *Indicates adjacent fat pad. Representative images ×
400 magnification. Scale bars = 50 μm. f CurveAlign analysis of relative collagen alignment following CT-FIRE fiber extraction as described in
“Methods”. 0 = perfectly random fibers, 1 = perfectly aligned fibers. Mean ± SEM, n = 4 tumors of each cell line/host genotype combination, 7–9
images per tumor. Repeated measures, group comparison, SAS Proc Mixed model. *p < 0.05, ****p < 0.001. WT wild-type
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signaling cascades in tumor epithelia away from the
positive prognostic mediator STAT5 toward pathways
that drive poorer outcomes, ERK1/2 and AKT. This is
associated with invasive protrusions of the primary
tumor that harbor collagen fibers angled perpendicularly
to the tumor mass, a hallmark of aggressive ERα +
tumors. This remodeling of the surrounding ECM in
conjunction with the ability of PRL to increase the
expression of mammary ECM components, suggests a
feedforward loop by which PRL can drive the metastasis
of ERα + cancers.
Additional files
Additional file 1: Clonal GFP+ TC2GR12 (TC2) and TC4GR5 (TC4) cells
are ERα+, PRLR+, and express the signal mediators, STAT5, AKT, and
ERK1/2. A Wild-type FVB/N mammary epithelial cells (MECs), parental TC2
and TC4 (pTC2, pTC4), and GFP+ TC2 and TC4 RNA were analyzed by
real-time PCR for expression of the rat prolactin (rPrl) transgene expressed
by NRL-PRL animals. MECs did not express the transgene as expected,
and transfection with GFP did not alter transgene expression. 1 =MECs; 2
= parental TC2; 3 = TC2GR12 (GFP+ TC2); 4 = parental TC4; 5 = TC4GR5
(GFP+ TC4). B TC2GR12 (TC2) and TC4GR5 (TC4) cells were grown on
tissue culture plastic, serum starved overnight, and protein lysates assayed
via immunoblotting with the indicated antibodies. (PDF 96 kb)
Additional file 2: Flow cytometry gating strategy to detect circulating
tumor cells. A-C Cultured TC cell lines were trypsinzed, fixed in 2% PFA,
and analyzed via flow cytometry. Gates were set to include size of the
cells (A), inclusion of APC auto-fluorescence (B), and selection of GFP+
cells (C). D-F Cleared blood samples were labelled with APC-conjugated
CD31, CD45 to mark hematopoietic cells and analyzed following the
gating strategy in A-C. Selection for tumor epithelial size (D),
APC-negative cells (E), and GFP+ circulating tumor epithelial cells (F).
Representative gating strategy shown. (PDF 377 kb)
Additional file 3: Conditions for immunohistochemical and
immunofluorescence antibodies. (PDF 256 kb)
Additional file 4: The mCol1a1 environment does not alter tumor PRLR
expression, and tumors express progesterone receptors in localized foci.
A TC tumors lysates were probed for PRLR. No significant differences
were observed between WT and mCol1a1 tumors. Mean ± SEM TC2
tumors: WT n = 7, mCol1a1 n = 6; TC4 tumors: WT n = 7, mCol1a1 n = 8.
(Mann-Whitney U test, p > 0.05). B Progesterone receptor
immunohistochemical analysis. Progesterone receptor is expressed in
localized foci (upper panel). Positive staining of ductal epithelium (lower
panel). Original magnifications × 200. Scale bar = 50 μm. (PDF 333 kb)
Additional file 5: Surface lung nodules. Lungs from animals with no
tumor cell transplants, and those from tumor bearing WT, and mCol1a1
animals. Arrows depict surface lung nodules observed under dissection
microscopy. Representative images. Scale bar = 2 mm. (PDF 434 kb)
Additional file 6: mCol1a1 reduces pSTAT5, and elevates pERK1/2 and
pAKT in TC4 tumors, shown by immunohistochemical analysis.
Immunohistochemical analysis of pSTAT5 (A), pERK1/2 (B), and pAKT
S473 (C) of TC4 tumors. Original magnification × 200. Scale bar = 50 μm.
(PDF 473 kb)
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